Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer

被引：21

作者：

Dass, CR ^{[1
]}

机构：

[1] Johnson & Johnson Res, Eveleigh 1430, Australia

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2002年 / 128卷 / 04期

关键词：

cationic liposome; lipoplex; oligonucleotide; cancer; immunostimulation;

D O I：

10.1007/s00432-001-0318-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent studies have highlighted the immunostimulatory nature of nucleic acids and the enhancement of such immunostimulation when nucleic acids are complexed to cationic liposomes to form cationic-lipid-nucleic-acid-complexes or lipoplexes. While such immunostimulation may have deleterious consequences for nucleic acid delivery, especially in the field of gene therapy, it may be harnessed for efficacious usage against the various forms of cancer.

引用

收藏

页码：177 / 181

页数：5

相关论文

共 47 条

[21] Multiple systemic expression of human inferferon-β in mice can be achieved upon repeated administration of optimized pcTG90-lipoplex [J].

Meyer, O ;

Schughart, K ;

Pavirani, A ;

Kolbe, HVJ .

GENE THERAPY, 2000, 7 (18) :1606-1611

[22]

Mui B, 2001, J PHARMACOL EXP THER, V298, P1185

[23] Non-antisense oligonucleotide approaches for experimental treatment of glioblastoma [J].

Neckers, LM ;

Kanekal, M ;

Connell, Y .

ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (02) :177-179

[24]

Needham D, 2000, CANCER RES, V60, P1197

[25] INTERLEUKIN-12, INTERFERON-GAMMA, AND TUMOR-NECROSIS-FACTOR-ALPHA ARE THE KEY CYTOKINES OF THE GENERALIZED SHWARTZMAN REACTION [J].

OZMEN, L ;

PERICIN, M ;

HAKIMI, J ;

CHIZZONITE, RA ;

WYSOCKA, M ;

TRINCHIERI, G ;

GATELY, M ;

GAROTTA, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (03) :907-915

[26]

Parker SE, 1996, CANCER GENE THER, V3, P175

[27] Liposome-mediated DNA vaccination: the effect of vesicle composition [J].

Perrie, Y ;

Frederik, PM ;

Gregoriadis, G .

VACCINE, 2001, 19 (23-24) :3301-3310

[28] Promoter attenuation in gene therapy: Interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression [J].

Qin, LH ;

Ding, YZ ;

Pahud, DR ;

Chang, E ;

Imperiale, MJ ;

Bromberg, JS .

HUMAN GENE THERAPY, 1997, 8 (17) :2019-2029

[29] Structural basis of DOTMA for its high intravenous transfection activity in mouse [J].

Ren, T ;

Song, YK ;

Zhang, G ;

Liu, D .

GENE THERAPY, 2000, 7 (09) :764-768

[30] Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization [J].

Reyes, L ;

Hartikka, J ;

Bozoukova, V ;

Sukhu, L ;

Nishioka, W ;

Singh, G ;

Ferrari, M ;

Enas, J ;

Wheeler, CJ ;

Manthorpe, M ;

Wloch, MK .

VACCINE, 2001, 19 (27) :3778-3786

← 1 2 3 4 5 →